drugset
drugset / Trial / NCT04148963

A Study of Staccato Loxapine (ADASUVE®) for Inhalation

NCT04148963 ↗

Phase 3 Unknown 150 enrolled Lee's Pharmaceutical Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.

Timeline

Start
2019-12-01
Primary completion
2020-05-01
Completion
2020-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject loxapine Small molecule 9.1 mg Inhaled

Indications

bipolar disorder schizophrenia